TRACON Pharmaceuticals logo

TRACON PharmaceuticalsNASDAQ: TCON

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 January 2015

Next earnings report:

22 November 2024

Last dividends:

N/A

Next dividends:

N/A
$170.38 K
-97%vs. 3y high
2%vs. sector
-vs. 3y high
-vs. sector
-106%vs. 3y high
14%vs. sector
-97%vs. 3y high
3%vs. sector

Price

regular market | Thu, 21 Nov 2024 15:27:25 GMT
$0.05+$0.02(+66.67%)

Dividend

No data over the past 3 years
$55.00 K-$2.84 M

Analysts recommendations

Institutional Ownership

TCON Latest News

TRACON Pharmaceuticals Announces it Will Wind Down Operations
globenewswire.com30 July 2024 Sentiment: NEGATIVE

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.

TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: POSITIVE

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call is scheduled for May 14, 2024 at 4:30 PM ET. Presenting on the call will be Charles Theuer, President & CEO, and Scott Brown, CFO. Joining the call will be Matthew Venezia from Alliance Global Partners. Thank you for joining us today. Please note that all participants are currently in listen-only mode.

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
GlobeNewsWire28 February 2024 Sentiment: POSITIVE

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
InvestorPlace21 November 2023 Sentiment: POSITIVE

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.

Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
InvestorPlace13 November 2023 Sentiment: NEGATIVE

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.

Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
InvestorPlace10 November 2023 Sentiment: POSITIVE

Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.

TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
Seeking Alpha09 November 2023 Sentiment: POSITIVE

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewsWire05 September 2023 Sentiment: POSITIVE

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:

TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
Seeking Alpha14 August 2023 Sentiment: NEUTRAL

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
GlobeNewsWire02 August 2023 Sentiment: POSITIVE

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

What type of business is TRACON Pharmaceuticals?

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

What sector is TRACON Pharmaceuticals in?

TRACON Pharmaceuticals is in the Healthcare sector

What industry is TRACON Pharmaceuticals in?

TRACON Pharmaceuticals is in the Biotechnology industry

What country is TRACON Pharmaceuticals from?

TRACON Pharmaceuticals is headquartered in United States

When did TRACON Pharmaceuticals go public?

TRACON Pharmaceuticals initial public offering (IPO) was on 30 January 2015

What is TRACON Pharmaceuticals website?

https://www.traconpharma.com

Is TRACON Pharmaceuticals in the S&P 500?

No, TRACON Pharmaceuticals is not included in the S&P 500 index

Is TRACON Pharmaceuticals in the NASDAQ 100?

No, TRACON Pharmaceuticals is not included in the NASDAQ 100 index

Is TRACON Pharmaceuticals in the Dow Jones?

No, TRACON Pharmaceuticals is not included in the Dow Jones index

When was TRACON Pharmaceuticals the previous earnings report?

No data

When does TRACON Pharmaceuticals earnings report?

The next expected earnings date for TRACON Pharmaceuticals is 22 November 2024